These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 16337719

  • 1. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.
    Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, Schlereth B, Handley A, King L, Hülsemann V, Tzatzaris M, Merkl K, Wulff N, Chaplin P.
    Vaccine; 2006 Mar 15; 24(12):2065-70. PubMed ID: 16337719
    [Abstract] [Full Text] [Related]

  • 2. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.
    Virology; 2005 Sep 01; 339(2):164-75. PubMed ID: 15993917
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.
    von Sonnenburg F, Perona P, Darsow U, Ring J, von Krempelhuber A, Vollmar J, Roesch S, Baedeker N, Kollaritsch H, Chaplin P.
    Vaccine; 2014 Sep 29; 32(43):5696-702. PubMed ID: 25149431
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
    Phelps AL, Gates AJ, Hillier M, Eastaugh L, Ulaeto DO.
    Vaccine; 2007 Jan 02; 25(1):34-42. PubMed ID: 16950548
    [Abstract] [Full Text] [Related]

  • 5. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
    Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS, VRC 201/203 Study Team.
    Vaccine; 2007 Feb 09; 25(8):1513-25. PubMed ID: 17126963
    [Abstract] [Full Text] [Related]

  • 6. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
    Coulibaly S, Brühl P, Mayrhofer J, Schmid K, Gerencer M, Falkner FG.
    Virology; 2005 Oct 10; 341(1):91-101. PubMed ID: 16061267
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults.
    Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, Monath TP.
    Vaccine; 2009 Mar 04; 27(10):1637-44. PubMed ID: 19071184
    [Abstract] [Full Text] [Related]

  • 8. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
    Wyatt LS, Earl PL, Eller LA, Moss B.
    Proc Natl Acad Sci U S A; 2004 Mar 30; 101(13):4590-5. PubMed ID: 15070762
    [Abstract] [Full Text] [Related]

  • 9. IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.
    Jones T.
    Curr Opin Mol Ther; 2008 Aug 30; 10(4):407-17. PubMed ID: 18683106
    [Abstract] [Full Text] [Related]

  • 10. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
    Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuss T, Hanschmann KM, Kalinke U, Erez N, Levin R, Velan B, Löwer J, Shafferman A, Sutter G.
    J Infect Dis; 2009 Jan 01; 199(1):39-48. PubMed ID: 19012492
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.
    Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH, Eisenberg RJ, Hartmann CJ, Jackson DL, Kulesh DA, Martinez MJ, Miller DM, Mucker EM, Shamblin JD, Zwiers SH, Huggins JW, Jahrling PB, Moss B.
    Nature; 2004 Mar 11; 428(6979):182-5. PubMed ID: 15014500
    [Abstract] [Full Text] [Related]

  • 14. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.
    Ferrier-Rembert A, Drillien R, Meignier B, Garin D, Crance JM.
    Vaccine; 2007 Nov 28; 25(49):8290-7. PubMed ID: 17964011
    [Abstract] [Full Text] [Related]

  • 15. [Development of a numerically additive combined vaccine against tetanus and smallpox].
    Mayr A, Baljer G, Wagner C, Sailer J.
    Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr 28; 259(2):206-18. PubMed ID: 2990123
    [Abstract] [Full Text] [Related]

  • 16. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
    Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P.
    PLoS One; 2016 Apr 28; 11(6):e0157335. PubMed ID: 27327616
    [Abstract] [Full Text] [Related]

  • 17. A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults.
    Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, Kemp T, Nichols R, Balser JP, Currie M, Monath TP.
    Vaccine; 2005 May 09; 23(25):3301-9. PubMed ID: 15837236
    [Abstract] [Full Text] [Related]

  • 18. New generation smallpox vaccines: a review of preclinical and clinical data.
    Artenstein AW.
    Rev Med Virol; 2008 May 09; 18(4):217-31. PubMed ID: 18283712
    [Abstract] [Full Text] [Related]

  • 19. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.
    Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von Krempelhuber A, Virgin G, Bädeker N, Vollmar J, Chaplin P.
    J Infect Dis; 2013 Mar 01; 207(5):749-58. PubMed ID: 23225902
    [Abstract] [Full Text] [Related]

  • 20. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
    McCurdy LH, Larkin BD, Martin JE, Graham BS.
    Clin Infect Dis; 2004 Jun 15; 38(12):1749-53. PubMed ID: 15227622
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.